Abdul M. Oseini, Roongruedee Chaiteerakij, Abdirashid M. Shire, Amaar Ghazale, Joseph Kaiya, Catherine D. Moser, Ileana Aderca, Teresa A. Mettler, Terry M. Therneau, Lizhi Zhang, Naoki Takahashi, Suresh T. Chari, Lewis R. Roberts – 14 June 2011 – Elevated serum immunoglobulin G4 (sIgG4) is a feature of autoimmune pancreatitis (AIP) and IgG4‐associated cholangitis (IAC); a >2‐fold increase in sIgG4 is considered highly specific for these disorders.

Carlos A. Apestegui, Olivier Julliard, Olga Ciccarelli, Dhang Khahn Ho Minh Duc, Jan Lerut – 14 June 2011

Hong Li, Chao Ge, Fangyu Zhao, Mingxia Yan, Chen Hu, Deshui Jia, Hua Tian, Miaoxin Zhu, Taoyang Chen, Guoping Jiang, Haiyang Xie, Ying Cui, Jianren Gu, Hong Tu, Xianghuo He, Ming Yao, Yongzhong Liu, Jinjun Li – 14 June 2011 – Angiopoietin‐like protein 4 (ANGPTL4) plays complex and often contradictory roles in vascular biology and tumor metastasis, but little is known about its function in hepatocellular carcinoma (HCC) metastasis.

Vincent Di Martino, Carine Richou, Jean‐Paul Cervoni, Jose M. Sanchez‐Tapias, Donald M. Jensen, Alessandra Mangia, Maria Buti, Frances Sheppard, Peter Ferenci, Thierry Thévenot – 14 June 2011 – Response‐guided pegylated interferon (peg‐IFN) plus ribavirin (P/R) therapy trials on genotype (G)1 and G2/G3 hepatitis C virus–infected patients provide contradictory results. We conducted meta‐analyses of randomized, controlled trials to address (1) the benefit of a 72‐week extended‐duration therapy in G1‐slow responders and (2) adequate shortened duration therapy in G1 and G2/G3‐rapid responders.

Heidi Barth, Jolanta Rybczynska, Romuald Patient, Youkyung Choi, Ronda K. Sapp, Thomas F. Baumert, Kris Krawczynski, T. Jake Liang – 14 June 2011 – Understanding the immunological correlates associated with protective immunity following hepatitis C virus (HCV) reexposure is a prerequisite for the design of effective HCV vaccines and immunotherapeutics. In this study we performed a comprehensive analysis of innate and adaptive immunity following HCV reexposure of two chimpanzees that had previously recovered from HCV‐JFH1 infection.

Giuseppe Indolfi, Melissa Sambrotta, Maria Moriondo, Chiara Azzari, Massimo Resti – 14 June 2011

Raymond D. Hickey, Joseph B. Lillegard, James E. Fisher, Travis J. McKenzie, Sean E. Hofherr, Milton J. Finegold, Scott L. Nyberg, Markus Grompe – 14 June 2011 – Hereditary tyrosinemia type I (HT1) results in hepatic failure, cirrhosis, and hepatocellular carcinoma (HCC) early in childhood and is caused by a deficiency in the enzyme fumarylacetoacetate hydrolase (FAH). In a novel approach we used the chimeric adeno‐associated virus DJ serotype (AAV‐DJ) and homologous recombination to target and disrupt the porcine Fah gene.

Maria Elias‐Miro, Marta Massip‐Salcedo, Monica Jimenez‐Castro, Carmen Peralta – 10 June 2011 – Strategies for improving the viability of steatotic donor livers could increase the number of organs suitable for transplantation. There is evidence that adiponectin, the most abundant adipose‐specific adipokine, acts as an anti‐obesity and anti‐inflammatory hormone. Here we review the signaling pathways of adiponectin and the possible therapies based on adiponectin regulation that have been examined or applied clinically.

James A. Thomas, John P. Iredale, Stuart J. Forbes – 10 June 2011

Monica B. Jimenez‐Castro, Arani Casillas‐Ramirez, Marta Massip‐Salcedo, Maria Elias‐Miro, Anna Serafin, Antoni Rimola, Juan Rodes, Carmen Peralta – 10 June 2011 – Numerous steatotic livers are discarded as unsuitable for transplantation (TR) because of their poor tolerance of ischemia/reperfusion (I/R). Cyclic adenosine 3′,5′‐monophosphate (cAMP)–elevating agents protect against I/R injury both in nonsteatotic livers that have been removed from non–heart‐beating donors and subjected to warm ischemia or cold ischemia (CIS) and in perfused, isolated livers.